ReviewBiomolecules & biomedicine2026
Low-dose metformin in the brain: A focused review of its novel mechanism of glucose lowering in type 2 diabetes.
Review in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metformin remains the first-line pharmacological therapy for type 2 diabetes mellitus (T2DM). While its glucose-lowering effects have primarily been attributed to peripheral actions, evidence indicates that it also crosses the blood-brain barrier (BBB) and can exert anti-diabetic effects from within the central nervous system (CNS). This focused review discusses metformin's central actions and how they might integrate with established peripheral mechanisms of glucose-lowering. We synthesized recent mechanistic studies conducted in murine models using systemic and intracerebroventricular metformin administration, brain-specific genetic loss- and gain-of-function approaches, neuronal activation mapping, electrophysiology, and pharmacological interrogation of autonomic and metabolic pathways. The evidence reviewed indicates that clinically relevant low concentrations of metformin in the brain engage a ventromedial hypothalamus (VMH)-steroidogenic factor 1 (SF1) neuron-Ras-proximate-1 (Rap1) signaling axis, which is essential for its glucose lowering action. Notably, metformin inhibits Rap1 in VMH SF1 neurons to reduce hyperglycemia. This central mechanism appears specific to metformin and is not shared by other approved antidiabetic agents. Current data also imply that the CNS effects of metformin operate in conjunction with peripheral pathways including hepatic AMP-activated protein kinase (AMPK) signaling and gut-derived glucagon-like peptide-1 (GLP-1) secretion, to produce its overall metabolic effect. Collectively, these findings support a model in which metformin lowers glucose through an orchestrated integration of a central Rap-1 dependent mechanism and peripheral metabolic actions. Additionally, the recognition of a central component to metformin's pharmacology expands the mechanistic framework of this cornerstone therapy and may inform future therapeutic strategies targeting integrated brain-metabolic pathways in T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.